|
 |
Messages from the Leadership
 |
|
Dr. Deisseroth comes to the
Sidney Kimmel Cancer Center from Yale University. At Yale, he served
as Chief of the School of Medicine’s Section of Medical Oncology,
The Yale Cancer Center’s Associate Director for Clinical Research,
and Director of its Genetic Therapy Program.
Prior to that, he was Chairman of the Department of Hematology at
the M.D. Anderson Cancer Center at the University of Texas, Chief
of Hematology/Oncology at the University of California, San Francisco’s
Veterans Administration Medical Center, and Head of the Experimental
Hematology Section of the Pediatric Oncology Branch of the National
Cancer Institute, National Institutes of Health, in Bethesda, MD |
Dr. Albert Deisseroth
President and CEO
Sidney Kimmel Cancer Center |
|
|
|
|
 |
|
|
"I am honored to be selected to lead the world-class team that has
been assembled at the Sidney Kimmel Cancer Center, ” says Deisseroth.
"The Center is already a visible force in the application of laboratory
discoveries to cancer treatment. Discoveries emanating from the work
of Ivor Royston and the other scientists at the Sidney Kimmel Cancer Center,
and the companies that have spun off from the Center have resulted in
exciting
clinical cancer trials in gene therapy and biological therapy.”
Albert Deisseroth, MD
President and CEO
 |
|
Cancer has been the leading
consumer of the health care dollar in the United States since the
year 2000. This disease has wrecked havoc in the lives of patients,
their families and their communities. The scope of this tragedy
will continue to increase as those at greatest risk, people over
age 50, become a larger segment of the population. Genetics and medical technology are now providing scientists with
the tools necessary to create more effective and less toxic treatments
for cancer. These new tools are creating a revolution in cancer
diagnosis and treatment. I feel grateful for the opportunity to lead
the board of trustees of the Sidney Kimmel Cancer Center in support
of our mission: to
apply laboratory discoveries to the development of new approaches
for prevention, earlier diagnosis and clinical interventions.
|
|
Geri Ann Warnke,
Chair
Sidney Kimmel Cancer Center Board of Trustees
|
|
|
In the past year, SKCC scientists
have developed genetic tests that can be used by oncologists to individualize
therapy so that each patient can access the treatment that is optimal
for their specific disease entity. Our team has created ways of targeting
chemotherapy drugs and radiation to the cancer cells and their vasculature,
sparing normal tissues, thereby, reducing side effects. Cancer vaccines
have been developed that could potentially be used to eradicate cancer
cells throughout the body reducing recurrence rates. These developments
have the potential to improve the outcome of cancer treatments to
the benefit of millions of people around the world.
Public support of cancer research has never been more important.
Every dollar has the potential to impact the lives of people who are
engaged in the struggle to overcome this devastating disease. My goal
for the coming year is to assemble the resources necessary to ensure
that basic research discoveries can be translated into clinical application
at the earliest possible time. I hope that you will join me in this
endeavor.
Geri Ann Warnke
Chair, Sidney Kimmel Cancer Center Board of Trustees |
| |
|
|
|
| |
|
|
|
